Corona Remedies officials will attend two major investor conferences in Mumbai this week, engaging with analysts and institutional investors through group and one-on-one meetings. The participation aims to provide market participants with updates on the company’s performance and outlook, utilizing only publicly available information to ensure regulatory compliance and transparency.

The engagements are scheduled for August 13 and 14, 2026, aligning with the timelines of the Emkay Global Investor Conference and the Equirus Investor Conference respectively. These interactions are critical for maintaining open communication channels with the investment community, allowing stakeholders to clarify queries regarding the company’s strategic direction and operational metrics without disclosing any unpublished price-sensitive information (UPSI).

Conference Schedule

The company has detailed the specific timing and nature of these engagements in its intimation to the stock exchanges. The schedule is as follows:

Regulatory Compliance

The intimation was issued pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates that listed entities disclose their participation in analyst or investor conferences to ensure equitable dissemination of information to all stakeholders.

Chetna Dharajiya, Company Secretary and Compliance Officer of Corona Remedies Limited, signed the disclosure on August 10, 2026. The notice explicitly states that no UPSI will be discussed during these sessions, reinforcing the company’s adherence to insider trading norms and fair disclosure practices.

Market Implications

While no new financial data will be released during these meetings, such conferences often serve as a barometer for investor sentiment. Analysts from Emkay Global and Equirus will likely focus on the company’s recent quarterly performance, pipeline developments, and broader industry trends affecting the pharmaceutical sector. The in-person format allows for more nuanced discussions compared to virtual interactions, potentially leading to deeper insights into management’s strategic priorities.

Investors are advised to monitor the company’s website at www.coronaremedies.com for any subsequent updates or changes to the schedule due to exigencies on the part of the host or the company. The disclosures were simultaneously filed with the Listing Operation Department of BSE Limited and the Listing Compliance Department of National Stock Exchange of India Limited.

Corona Remedies has made the audio recording of its Q1 FY27 earnings conference call available to investors and analysts, providing direct access to management’s commentary on the company’s performance for the quarter ended June 30, 2026. The availability of this recording ensures transparency regarding the unaudited financial results for the first quarter of FY27, allowing stakeholders to review the detailed discussion held with market participants.

The company notified the Listing Operation Department at BSE Limited and the Listing Compliance Department at National Stock Exchange of India Limited on August 03, 2026. This disclosure was made in continuation of a letter dated July 22, 2026, and is compliant with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The regulation mandates timely dissemination of material information to prevent information asymmetry among investors.

The audio recording covers the post-earnings quarterly call where analysts and investors queried the management about the financial outcomes. The session focused on the unaudited financial results for the first quarter and three months ended June 30, 2026. Investors can access the recording directly through the company’s website at the designated URL provided in the exchange filing.

Key Details

Chetna Dharajiya, Company Secretary and Compliance Officer of Corona Remedies Limited, signed the communication. The digital signature was applied on August 03, 2026, at 16:02:47 IST. The filing serves as an official record of the company’s compliance with disclosure norms regarding investor interactions following the release of quarterly financial results.